INTELLIGENT BIO SOLUTIONS INC. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Intelligent Bio Solutions completed a multi-site clinical study of its Intelligent Fingerprinting Drug Screening System across three U.S. sites, achieving 98.2% overall accuracy, 94.6% sensitivity, and 100% specificity for detecting codeine. This represents material improvement from the prior November 2024 study (94% accuracy, 82% sensitivity). The company accelerated its FDA 510(k) submission timeline and now plans to file in September 2026, with no dollar amounts, counterparties, or share counts disclosed in this announcement.
Why this rating
Regulatory milestone is material for $11.7M biotech: 510(k) clearance is prerequisite for U.S. market entry and revenue. Study improvement directly supports pathway to commercialization and potential transformational shift from non-U.S. only operations.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $2.58 ▲ 6.19% | at our read · unknown $2.43 | +10 min · unknown $2.43 ▲ 0.00% | +30 min · unknown $2.43 ▲ 0.00% | +1 hr · unknown $2.43 ▲ 0.00% | +4 hrs pending |
The stock had already moved -5.82% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.